BALTIMORE, Aug. 31,
2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc.
(NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage
pharmaceutical company focused on the development and
commercialization of a novel synthetic THC analog named MIRA1a,
will participate in the 6th Annual Cannabinoid-Derived
Drug Development Summit taking place September 11-13, 2023 in Boston, MA.
Dr. Adam Kaplin, President and
Chief Scientific Officer of MIRA Pharmaceuticals, will be featured
as a keynote speaker during the conference. Dr. Kaplin will be
discussing the development of MIRA1a, and its unique
pharmacodynamic properties in conjunction with preclinical studies
findings, which taken together suggest that: 1) MIRA1a has
anti-anxiety effects that minimize the risk of increased anxiety at
higher doses seen with THC, 2) MRIA1a lacks the side effects seen
with THC in animal models of psychosis, which translates into
paranoia in humans, and 3) MIRA1a is able to significantly enhance
cognitive performance when given once immediately before testing, a
finding not previously seen with cannabinoids.
Dr. Kaplin will be presenting research on MIRA1a demonstrating
that it is a novel compound with a distinct pharmacodynamic
profile, acting as a partial agonist at the CB1 receptor and a
potent agonist at the CB2 receptor. Unlike THC, which exhibits a
biphasic dose response and associated varying effects on anxiety,
MIRA1a's partial agonism at CB1 results in a monophasic dose
response, suggesting a more stable anti-anxiety effect across its
dosage range. Preclinical tests indicate that MIRA1a does not
produce catalepsy in mice, suggesting it will sidestep the
psychosis-like side effects commonly seen with THC. Moreover,
MIRA1a's potency is 8 times and 30 times higher as an agonist at
the CB2 receptor than THC and CBD, respectively, which predicts it
will have robust anti-neuropathic, anti-inflammatory, and
neuroprotective properties. Most intriguingly, MIRA1a has been
shown to improve cognitive performance, offering a promising avenue
for the treatment of cognitive impairments like dementia.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a
pre-clinical-stage pharmaceutical development company developing an
unscheduled novel synthetic THC analog. This novel compound is
currently under investigation for treating adult patients suffering
from anxiety and cognitive decline, often associated with
early-stage dementia. MIRA1a, if approved by the FDA, could mark a
significant advancement in addressing various neuropsychiatric,
inflammatory, and neurologic diseases and disorders. Based on
pre-clinical and animal studies conducted by the Company, the
Company believes that MIRA1a may enhance the therapeutic potential
for treating anxiety, cognitive decline, and neuropathic pain
without the side effects of plant-based THC. Furthermore, the
Company's studies indicate that MIRA1a may counteract the adverse
cognitive effects often seen with THC, thereby potentially
unmasking previously unseen positive therapeutic effects, such as
cognitive performance enhancement.
The U.S. Drug Enforcement Administration (DEA)'s scientific
review of MIRA1a concluded that MIRA1a would not be considered a
controlled substance or listed chemical under the Controlled
Substances Act (CSA) and its governing regulations.
Additional information about the Company is available
at: www.mirapharmaceuticals.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the Company's current expectations. These forward-looking
statements include, without limitation, references to the Company's
expectations regarding the closing of the public offering and its
anticipated use of net proceeds from the offering. These statements
are not guarantees of future performance and are subject to certain
risks, uncertainties and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, risks and uncertainties related to the satisfaction
of customary closing conditions related to the public offering, or
factors that result in changes to the Company's anticipated use of
proceeds. These and other risks and uncertainties are described
more fully in the section captioned "Risk Factors" in the Company's
Registration Statement on Form S-1, as amended, related to the
public offering (SEC File No. File No. 333-273074). Forward-looking
statements contained in this announcement are made as of this date,
and the Company undertakes no duty to update such information
except as required under applicable law.
View original
content:https://www.prnewswire.com/news-releases/mira-pharmaceuticals-to-participate-in-6th-annual-cannabinoid-derived-drug-development-summit-301914436.html
SOURCE MIRA Pharmaceuticals, Inc.